Trial · NCT05839951
An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
NCT05839951, Completed, Bayer
3 sourcestrials-2026-11-12-0.4.0
Cite this record
ConductScience Library. An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions. Trials, record NCT05839951. Release trials-2026-11-12-0.4.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05839951
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- An Observational Study Called STAR-T to Learn More About the Sequential Treatment With Regorafenib and TAS-102 in Adults With Metastatic Colorectal Cancer Under Real World Conditions
- NCT number
- NCT05839951
- Status
- Completed
- Enrollment
- 818 participants, actual
- Lead sponsor
- Bayer
- Conditions
- Metastatic Colorectal Cancer (mCRC)
- Interventions
- Regorafenib (BAY73-4506, Stivarga®), TAS-102 (trifluridine and tipiracil, Lonsurf®), Bevacizumab
- First posted
- 2023-05-03
- Last updated
- 2025-11-12
Source ClinicalTrials.gov
Registered outcomes10
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Cohort R-T or Cohort T-R: Descriptive analysis of demographic | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | Demographic includes age, gender, race and ethnicity, insurance. |
| Primary | Cohort R-T or Cohort T-R: Descriptive analysis of clinical characteristics | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | Clinical characteristics includes number and type of prior therapies patient received for mCRC, stage at initial diagnosis, performance status, histology, time since metastatic diagnosis, Line of Treatment (LOT) of index treatment |
| Primary | Cohort R-T or Cohort T-R: Descriptive analysis of biomarker Kirsten rat sarcoma 2 viral oncogene homolog (KRAS) | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | Biomarker B-Raf Proto-Oncogene (BRAF) and Mismatch Repair / Microsatellite instability (MMR/MSI) will be explored depending on data availability. |
| Secondary | Cohort R-T or Cohort T-R: Duration of sequential treatment | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | |
| Secondary | Cohort R-T or Cohort T-R: Proportion of patients receiving subsequent therapies | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | |
| Secondary | Cohort R-T or Cohort T-R: Type of subsequent therapies | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | |
| Secondary | Cohort R-T or Cohort T-R: Frequency of myelosuppression related medical interventions during sequential treatment | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | Myelosuppression related medical interventions \[e.g., use of Granulocyte colony stimulating factors (G-CSF)\] |
| Secondary | Cohort R-T or Cohort T-R: Frequency and incidence rate of neutropenia during sequential treatment | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | |
| Secondary | Cohort R-T or Cohort T-R: Number of patients with health care resource utilizations during sequential treatment | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) | Health care resource utilizations includes office/hospital visit and lab visit. |
| Secondary | Cohort R-T or Cohort T-R: Overall survival of patients with Regorafenib followed by TAS-102 and vice versa in 3rd line treatment and 4th line treatment | Retrospective analysis period is from Jan 2015 to Sep 2022 (or 3 months prior to the latest data cutoff date) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Source
- Release
- trials-2026-11-12-0.4.0
- Release manifest SHA-256
- 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4
- Registry capture
- 2026-11-12
- Results copy, AACT
- 2026-03-23
- NIH clinical studies file
- 2026-11-13
Source ClinicalTrials.gov
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNone stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05839951
GET https://conductscience.org/api/trials/v1/NCT05839951/registered